Skip to main content
Premium Trial:

Request an Annual Quote

Lion CIO Departs as Company Streamlines

NEW YORK, Feb. 21 - At the end of a long period of 'streamlining' for Lion Bioscience, Reinhard Schneider, chief information officer, is leaving, and the company is considering reducing its external supervisory board from 6 to 3 members, Lion said today.

 

Schneider will continue to consult for the company. He plans to "pursue new challenges in a more scientific environment," according to a company statement.

 

Schneider, a cofounder of Lion and a former scientist at the European Molecular Biology Laboratory, had expressed a desire to return to pure science some time ago, Lion CEO Friedrich von Bohlen told GenomeWeb.

 

Reiner Doelle, a 30-year veteran of IBM, has been hired to head up software development, but will not hold a senior executive-level post.

 

As CSO Jan Mous left in early January, Lion's management team has gone from 5 to 3 executives thus far this year.

 

This latest management announcement comes after the company reduced its headcount from "north of 500" to around 300, as part of its effort to focus solely on providing informatics solutions and exit from the drug discovery business, according to von Bohlen.

 

The company may follow its internal management changes by narrowing its supervisory board from 6 to 3 members. German companies are only allowed to have external supervisory boards of 3, 6, or 9 members, von Bohlen said.

 

This smaller board is likely to include J rgen Dormann, the current chair, and two other new members.

 

The company will not make a final decision on whether to propose this move until June, and the proposal cannot be finalized until August, when the shareholders meet.

 

Lion is "focusing on new, experienced people and keeping the organization and the management teams lean, but mean," von Bohlen said.

 

For further information, see the company statement.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.